VACCITECH PLC
Vaccitech plc (BRNS) is a clinical-stage biotechnology company developing T‑cell-focused vaccines and immunotherapies for infectious diseases and cancer. Originating from academic research, the company advances a prime‑boost platform designed to stimulate cellular immunity and has multiple programmes at various stages of clinical development. Key value drivers for investors are clinical trial readouts, regulatory milestones and partner or licensing agreements, any of which can move the share price materially. With a market capitalisation of roughly $56.75m it is a small‑cap, higher-volatility stock; financing needs, trial setbacks or delays can lead to dilution and sharp price swings. Commercial revenue is limited at this stage, so progress often looks binary and timeline-dependent. This is general educational information, not personalised financial advice. Values can rise and fall and returns are not guaranteed — consider pipeline timing, cash runway and personal risk tolerance, and consult a professional for tailored guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VACCITECH PLC's stock with a target price of $5.4, indicating growth potential.
Financial Health
Vaccitech is producing decent revenue and cash flow, with solid value per share indicating stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BRNS
Analyst All-Stars
Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.
Published: June 18, 2025
Explore BasketPotential Bargains
These companies are trading below what experts believe they're truly worth. Our analysts have carefully selected stocks with significant upside potential, representing hidden opportunities for growth as they move toward their projected valuations.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory milestones can create sharp share-price moves, though outcomes are uncertain and timelines can slip.
Platform Science Focus
A prime‑boost platform aims to stimulate T‑cell immunity across indications, offering scientific potential but with clinical execution risk.
Partnerships Matter
Collaborations or licensing deals may de‑risk programmes and provide funding, yet dependence on partners and terms can affect value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
